PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression

The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy

(2018) Vancheswaran Gopalakrishnan et al.   CANCER CELL

Ibrutinib treatment improves T cell number and function in CLL patients

(2017) Meixiao Long et al.   JOURNAL OF CLINICAL INVESTIGATION

Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway

(2017) K Kondo et al.   LEUKEMIA

Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia

(2017) Noelia Purroy et al.   Cold Spring Harbor Perspectives in Medicine

The Immune System Bridges the Gut Microbiota with Systemic Energy Homeostasis: Focus on TLRs, Mucosal Barrier, and SCFAs

(2017) Martina Spiljar et al.   Frontiers in Immunology

PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells

(2017) Jacob S. Bowers et al.   Frontiers in Immunology

Chronic lymphocytic leukaemia

(2017) Thomas J. Kipps et al.   Nature Reviews Disease Primers

Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells

(2017) Barry D. Hock et al.   PLoS One

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

(2016) B. L. Lampson et al.   BLOOD

LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia

(2016) Phuong-Hien Nguyen et al.   CANCER CELL

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment

(2016) Andrew Stiff et al.   CANCER RESEARCH

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma

(2016) M. Ruella et al.   CLINICAL CANCER RESEARCH

The microbiota in adaptive immune homeostasis and disease

(2016) Kenya Honda et al.   NATURE

Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape

(2016) Malte Mohme et al.   Nature Reviews Clinical Oncology

‘Acute myeloid leukemia: a comprehensive review and 2016 update’

(2016) I De Kouchkovsky et al.   Blood Cancer Journal

Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E -TCL1 CLL mouse model

(2015) F. McClanahan et al.   BLOOD

Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model

(2015) Franz J. Gassner et al.   BRITISH JOURNAL OF HAEMATOLOGY

Normalization of Host Intestinal Mucus Layers Requires Long-Term Microbial Colonization

(2015) Malin E.V. Johansson et al.   Cell Host & Microbe

The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL

(2015) K Balakrishnan et al.   LEUKEMIA

CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model

(2015) T Kocher et al.   LEUKEMIA

CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs

(2014) R. Jitschin et al.   BLOOD

Innate PI3K p110  Regulates Th1/Th17 Development and Microbiota-Dependent Colitis

(2014) E. C. Steinbach et al.   JOURNAL OF IMMUNOLOGY

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

(2014) Khaled Ali et al.   NATURE

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells

(2013) M. F. Pascutti et al.   BLOOD

Accelerated progression of chronic lymphocytic leukemia in E -TCL1 mice expressing catalytically inactive RAG1

(2013) V. K. Nganga et al.   BLOOD

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

(2013) J. A. Woyach et al.   BLOOD

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

(2013) J. A. Dubovsky et al.   BLOOD

Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide

(2013) A. G. Ramsay et al.   BLOOD

Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo

(2013) Gloria Lutzny et al.   CANCER CELL

Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype

(2013) Joachim Rudolf Göthert et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation

(2013) R. Maffei et al.   HAEMATOLOGICA

The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells

(2013) Stefania Fiorcari et al.   PLoS One

ROR1 can interact with TCL1 and enhance leukemogenesis in E -TCL1 transgenic mice

(2013) G. F. Widhopf et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production

(2012) J. C. Riches et al.   BLOOD

Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals

(2012) Rosa Lapalombella et al.   CANCER CELL

Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia

(2012) S. E. M. Herman et al.   CLINICAL CANCER RESEARCH

Tcl1 interacts with Atm and enhances NF- B activation in hematologic malignancies

(2011) E. Gaudio et al.   BLOOD

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

(2011) J. Hoellenriegel et al.   BLOOD

Analysis of the chronic lymphocytic leukemia coding genome: role ofNOTCH1mutational activation

(2011) Giulia Fabbri et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL

(2011) J Piñón Hofbauer et al.   LEUKEMIA

Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia

(2011) J. A. Burger   Hematology-American Society of Hematology Education Program

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia

(2010) Q. Zhou et al.   BLOOD

Phosphatidylinositol 3-kinase-  inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

(2010) S. E. M. Herman et al.   BLOOD

Epigenetic alterations in a murine model for chronic lymphocytic leukemia

(2010) Shih-Shih Chen et al.   CELL CYCLE

Altered Macrophage Function Contributes to Colitis in Mice Defective in the Phosphoinositide-3 Kinase Subunit p110δ

(2010) Jennifer K. Uno et al.   GASTROENTEROLOGY

The p110  Isoform of Phosphatidylinositol 3-Kinase Controls the Quality of Secondary Anti-Leishmania Immunity by Regulating Expansion and Effector Function of Memory T Cell Subsets

(2010) D. Liu et al.   JOURNAL OF IMMUNOLOGY

Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels

(2009) Rong Yuan et al.   AGING CELL

PKC  is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKC  as a therapeutic target in chronic lymphocytic leukemia

(2009) C. Holler et al.   BLOOD

Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia

(2009) M. J. Szczepanski et al.   CLINICAL CANCER RESEARCH

E -TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction

(2009) G. Gorgun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation

(2008) J. A. Burger et al.   BLOOD

Regulatory T cells and treatment of cancer

(2008) Tyler J Curiel   CURRENT OPINION IN IMMUNOLOGY

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug

(2008) Alan G. Ramsay et al.   JOURNAL OF CLINICAL INVESTIGATION

The p110δ of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation

(2008) Hailong Guo et al.   JOURNAL OF EXPERIMENTAL MEDICINE